Time to clozapine initiation in treatment-resistant schizophrenia in the United Arab Emirates: retrospective cohort study with international benchmarking

Résumé

Background Clozapine is the only antipsychotic with demonstrated efficacy in treatment-resistant schizophrenia, but remains underutilised worldwide, with limited data from the Middle East and North Africa. Aims We examined clozapine initiation, delays and outcomes in a large United Arab Emirates (UAE) cohort. Method We conducted a retrospective cohort study of patients prescribed antipsychotics at a tertiary psychiatric hospital in the UAE (2018–2025). Treatment resistance was defined as two or more distinct sequential adequate antipsychotic trials, each for at least 6 weeks and at a drug-specific therapeutic dose (defined daily dose method). Outcomes were clozapine initiation, time to initiation, guideline concordance (within 3 months) and hospital admissions. Results Of 6256 patients with schizophrenia spectrum diagnoses prescribed antipsychotics, 1738 (27.8%) met treatment-resistance criteria. Clozapine was initiated in 129 (7.4%; 95% CI 6.3–8.8%), comparably between expatriates and nationals (7.7 v . 7.1%; p = 0.72). Among 76 delayed initiators, median delay was 13.2 months (interquartile range 2.2–32.5) and 26.3% were guideline-concordant. The number of adequate trials most strongly predicted initiation (adjusted odds ratio 1.98, 95% CI 1.70–2.30; p < 0.001). Delayed initiation was associated with higher hospital admission rates (adjusted incidence rate ratios 2.5–2.6 for delays up to 24 months; p < 0.05), although an exploratory propensity-weighted analysis was underpowered ( β = −2.57; p = 0.12). Conclusions Clozapine remains underutilised in this setting, with fewer than 1 in 12 treatment-resistant patients receiving it and only a quarter of delayed initiators achieving guideline-concordant timing. These findings highlight an evidence-to-practice gap and support strategies for earlier clozapine access.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0